NEW: FDA's Julie Tierney and Dr. Nicole Verdun to Speak at ASGCT's Policy Summit (Sept. 23-24). Register Now!
Insight Series
This session will illustrate recent advances in our understanding of how pathogen recognition and consequent innate immune signaling may impact non-viral delivery of nucleic acids for better or for worse.
Moderators: Federico Mingozzi, PhD - Spark Therapeutics, and Stefan Radtke, PhD - Fred Hutchinson Cancer Research Center
Kate Fitzgerald, PhD - University of Massachusetts Chan Medical School Toll-Like receptor signaling, innate nucleic acid sensors, and the innate immune response
Marina Dobrovolskaia, PhD - Frederick National Laboratory for Cancer Research Immunological Properties of LNPs & Nucleic Acid-Based APIs
Pedro Cejas, PhD - Spark Therapeutics Overcoming barriers to safe and efficient non-viral delivery of DNA
Watch on demand
Register for more sessions during ASGCT Insights Week, Oct. 16-20. Members and registrants can watch on demand!
Oct. 16: Best of ASGCT: Annual Meetings Recent Top Abstracts Revisited
Oct. 17: Risk Assessment of Lentiviral and AAV Gene Therapy Vectors
Oct. 18: Risk Assessment for Gene Editing Technologies and Outcomes
Oct. 19: Treating Genetic Diseases Prior to Birth from Stem Cells to Gene Delivery
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico